Theravance Biopharma, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Theravance Biopharma, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q2 2024.
  • Theravance Biopharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $31.8M, a 17.3% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $31.8M -$6.64M -17.3% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $35.4M -$3.84M -9.8% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $36.3M -$3.84M -9.57% Dec 31, 2023 10-Q 2024-08-08
Q3 2023 $37.6M -$2.42M -6.04% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $38.5M -$2.66M -6.47% Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $39.2M -$145K -0.37% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $40.1M +$436K +1.1% Dec 31, 2022 10-K 2024-03-01
Q3 2022 $40M -$726K -1.78% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $41.1M -$396K -0.95% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $39.3M -$3.17M -7.45% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $39.7M -$3.57M -8.25% Dec 31, 2021 10-K 2023-03-01
Q3 2021 $40.7M -$3.67M -8.27% Sep 30, 2021 10-Q 2021-11-08
Q2 2021 $41.5M -$3.68M -8.14% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $42.5M -$3.59M -7.78% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $43.3M -$3.34M -7.18% Dec 31, 2020 10-K 2022-02-28
Q3 2020 $44.4M -$2.36M -5.06% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $45.2M -$2.65M -5.53% Jun 30, 2020 10-Q 2020-08-10
Q1 2020 $46.1M -$2.76M -5.64% Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $46.6M Dec 31, 2019 10-K 2021-02-26
Q3 2019 $46.8M Sep 30, 2019 10-Q 2019-11-08
Q2 2019 $47.8M Jun 30, 2019 10-Q 2019-08-05
Q1 2019 $48.9M Mar 31, 2019 10-Q 2019-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.